Literature DB >> 27869478

Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.

Shanmugam Saravanan1, Bagavathi Kausalya1, Selvamurthi Gomathi1, Sathasivam Sivamalar1, Balakrishnan Pachamuthu1, Poongulali Selvamuthu1, Amrose Pradeep1, Solomon Sunil1,2, Sarvode N Mothi3, Davey M Smith4, Rami Kantor5.   

Abstract

We have analyzed reverse transcriptase (RT) region of HIV-1 pol gene from 97 HIV-infected children who were identified as failing first-line therapy that included first-generation non-nucleoside RT inhibitors (Nevirapine and Efavirenz) for at least 6 months. We found that 54% and 65% of the children had genotypically predicted resistance to second-generation non-nucleoside RT inhibitors drugs Etravirine (ETR) and Rilpivirine, respectively. These cross-resistance mutations may compromise future NNRTI-based regimens, especially in resource-limited settings. To complement these investigations, we also analyzed the sequences in Stanford database, Monogram weighted score, and DUET weighted score algorithms for ETR susceptibility and found almost perfect agreement between the three algorithms in predicting ETR susceptibility from genotypic data.

Entities:  

Keywords:  HIV drug resistance; HIV drug resistance in South India; HIV in children; etravirine; etravirine resistance in children; rilpivirine; subtype C resistance

Mesh:

Substances:

Year:  2016        PMID: 27869478      PMCID: PMC5695734          DOI: 10.1089/AID.2016.0133

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   1.723


  26 in total

1.  An automated genotyping system for analysis of HIV-1 and other microbial sequences.

Authors:  Tulio de Oliveira; Koen Deforche; Sharon Cassol; Mika Salminen; Dimitris Paraskevis; Chris Seebregts; Joe Snoeck; Estrelita Janse van Rensburg; Annemarie M J Wensing; David A van de Vijver; Charles A Boucher; Ricardo Camacho; Anne-Mieke Vandamme
Journal:  Bioinformatics       Date:  2005-08-02       Impact factor: 6.937

2.  Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.

Authors:  Wendy P Bannister; Lidia Ruiz; Alessandro Cozzi-Lepri; Amanda Mocroft; Ole Kirk; Schlomo Staszewski; Clive Loveday; Anders Karlsson; Antonella d'Arminio Monforte; Bonaventura Clotet; Jens D Lundgren
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177

3.  Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.

Authors:  George L Melikian; Soo-Yon Rhee; Vici Varghese; Danielle Porter; Kirsten White; Jonathan Taylor; William Towner; Paolo Troia; Jeffrey Burack; Edwin Dejesus; Gregory K Robbins; Kristin Razzeca; Ron Kagan; Tommy F Liu; W Jeffrey Fessel; Dennis Israelski; Robert W Shafer
Journal:  J Antimicrob Chemother       Date:  2013-08-09       Impact factor: 5.790

4.  Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.

Authors:  Christine Katlama; Bonaventura Clotet; Anthony Mills; Benoit Trottier; Jean-Michel Molina; Beatriz Grinsztejn; William Towner; Richard Haubrich; Steven Nijs; Johan Vingerhoets; Brian Woodfall; James Witek
Journal:  Antivir Ther       Date:  2010

5.  Sequence quality analysis tool for HIV type 1 protease and reverse transcriptase.

Authors:  Allison K Delong; Mingham Wu; Diane Bennett; Neil Parkin; Zhijin Wu; Joseph W Hogan; Rami Kantor
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-26       Impact factor: 2.205

6.  Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants.

Authors:  Kalyan Das; Arthur D Clark; Paul J Lewi; Jan Heeres; Marc R De Jonge; Lucien M H Koymans; H Maarten Vinkers; Frederik Daeyaert; Donald W Ludovici; Michael J Kukla; Bart De Corte; Robert W Kavash; Chih Y Ho; Hong Ye; Mark A Lichtenstein; Koen Andries; Rudi Pauwels; Marie-Pierre De Béthune; Paul L Boyer; Patrick Clark; Stephen H Hughes; Paul A J Janssen; Eddy Arnold
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

7.  Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq 2.0 and an in-house method.

Authors:  S Saravanan; M Vidya; P Balakrishnan; P Balakrishanan; N Kumarasamy; Sunil S Solomon; S Solomon; Rami Kantor; David Katzenstein; Bharat Ramratnam; Kenneth H Mayer
Journal:  J Virol Methods       Date:  2009-04-02       Impact factor: 2.014

8.  High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines.

Authors:  Khady Kebe; Moussa Thiam; Ndeye Rama Diagne Gueye; Halimatou Diop; Aïchatou Dia; Haby Signate Sy; Charlotte Charpentier; Laurent Belec; Souleymane Mboup; Coumba Toure Kane
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-03       Impact factor: 2.205

9.  Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.

Authors:  Zehava Grossman; Valery Istomin; Diana Averbuch; Margalit Lorber; Klaris Risenberg; Itzchak Levi; Michael Chowers; Michael Burke; Nimrod Bar Yaacov; Jonathan M Schapiro
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

10.  The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance.

Authors:  Robert J Gifford; Tommy F Liu; Soo-Yon Rhee; Mark Kiuchi; Stephane Hue; Deenan Pillay; Robert W Shafer
Journal:  Bioinformatics       Date:  2009-03-20       Impact factor: 6.937

View more
  6 in total

1.  Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa.

Authors:  Kevin D McCormick; Kerri J Penrose; Chanson J Brumme; P Richard Harrigan; Raquel V Viana; John W Mellors; Urvi M Parikh; Carole L Wallis
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 2.  The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Authors:  Ying Mu; Sunitha Kodidela; Yujie Wang; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2018-09-20       Impact factor: 3.889

3.  Structural investigation of 2-naphthyl phenyl ether inhibitors bound to WT and Y181C reverse transcriptase highlights key features of the NNRTI binding site.

Authors:  Vincent N Duong; Joseph A Ippolito; Albert H Chan; Won-Gil Lee; Krasimir A Spasov; William L Jorgensen; Karen S Anderson
Journal:  Protein Sci       Date:  2020-08-05       Impact factor: 6.725

4.  Molecular Characterization of the pol Gene of Vertically Transmitted HIV-1 Strains in Children with Virological Failure.

Authors:  Ramesh Karunaianantham; Manohar Nesa Kumar; Bindu Gopalan; Hemalatha Haribabu; Luke Elizabeth Hanna; G N Sanjeeva; Devarajulu Reddy; Anita Shet; Soumya Swaminathan; Chandrasekaran Padmapriyadarsini
Journal:  AIDS Res Hum Retroviruses       Date:  2022-05-16       Impact factor: 1.723

5.  HIV-1 Treatment Failure, Drug Resistance, and Clinical Outcomes in Perinatally Infected Children and Adolescents Failing First-Line Antiretroviral Therapy in Western Kenya.

Authors:  Winstone Nyandiko; Sabina Holland; Rachel Vreeman; Allison K DeLong; Akarsh Manne; Vladimir Novitsky; Festus Sang; Celestine Ashimosi; Anthony Ngeresa; Ashley Chory; Josephine Aluoch; Millicent Orido; Eslyne Jepkemboi; Soya S Sam; Angela M Caliendo; Samuel Ayaya; Joseph W Hogan; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2022-02-01       Impact factor: 3.771

6.  Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Authors:  Oliver T Stirrup; David T Dunn; Anna Tostevin; Caroline A Sabin; Anton Pozniak; David Asboe; Alison Cox; Chloe Orkin; Fabiola Martin; Patricia Cane
Journal:  AIDS Res Ther       Date:  2018-04-16       Impact factor: 2.250

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.